Tislelizumab Receives EU Approval in 3 Indications for First- and Second-Line NSCLC
Tislelizumab has been approved in Europe across 3 indications in the first and second line for select patients with non–small cell lung cancer.
Source: onclive.com
Page 3 - Nsclc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nsclc Today - Breaking & Trending Today
Imfinzi Improves Survival, Time to Progression in LS-SCLC
Some patients with limited-stage small cell lung cancer experienced overall survival benefits and progression-free survival via treatment with Imfinzi.
Source: curetoday.com
Phase 3 Trial Launches for Keytruda, MK-1084 in KRAS-Mutant NSCLC
A clinical trial has started to evaluate the investigational drug MK-1084 and Keytruda among some patients with metastatic non-small cell lung cancer.
Source: curetoday.com
Neoadjuvant Chemoimmunotherapy Shows Superiority in Non–Small Cell Lung Cancer Treatment
The study compared the adverse events and surgical, pathological, and efficacy outcomes associated with neoadjuvant chemoimmunotherapy vs chemotherapy, particularly focusing on patients with PD-L1 levels less than 1%.
Source: ajmc.com
Tomivosertib Development in Frontline NSCLC Ending After Findings from KICKSTART Trial
Data from the phase 2 KICKSTART trial of tomivosertib plus pembrolizumab do not support the combination's use in patients with non–small cell lung cancer.
Source: onclive.com